Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.67 |
| ▸ | FNTA | P49354 | 11/20 | 0.63 |
| ▸ | FNTB | P49356 | 11/20 | 0.63 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498572 | 0.92 | CYP3A4 (0.57) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL13573672 | 0.91 | CYP3A4 (0.70) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL1683558 | 0.90 | FNTA (0.79) | CYP3A4FNTAFNTB | |
| (S)-Tipifarnib SCHEMBL4429738 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL21544535 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL23633189 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| (S)-Tipifarnib SCHEMBL30436988 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL22772860 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL8097 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL29371885 | 0.88 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | claimed |
| EP-1809265-A4 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | claimed |
| EP-1811984-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Exonhit Therapeutics SA (FR) | 2007-08-01 | — | — | EP | claimed |
| EP-1809265-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006051423-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE | EXONHIT THERAPEUTICS SA (FR) | 2006-05-18 | — | — | WO | claimed |
| US-20060106060-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-05-18 | — | — | US | claimed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | claimed |
| EP-1162201-B1 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-29 | — | — | EP | claimed |
| WO-2001064199-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH TAXANE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | claimed |
| WO-2001062234-A2 | DOSING REGIMEN | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-30 | — | — | WO | claimed |
| WO-2001056552-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-09 | — | — | WO | claimed |
| EP-1094839-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH $i(IN VIVO) RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| EP-1094815-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING ARTHROPATHIES | Janssen Pharmaceutica N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| US-6037350-A | USEFUL AS ANTICANCER AGENTS FOR TUMORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-03-14 | — | — | US | claimed |
| WO-2000001411-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH IN VIVO RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-13 | — | — | WO | claimed |
| WO-2000001386-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING ARTHROPATHIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-13 | — | — | WO | claimed |
| EP-0865440-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-23 | — | — | EP | claimed |
| WO-1997021701-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | CYP3A4 2969/4885FNTA 1/4885FNTB 3/4885 |
| US-20060106060-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, GBA1 | CYP3A4 3912/4885FNTA 10/4885FNTB 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.